Latigo Biotherapeutics prices $345.6M IPO at $18 per share
Latigo Biotherapeutics priced its IPO at $18.00 per share, selling 19.2 million shares for expected gross proceeds of $345.6 million, per the company’s Aug. 6, 2026 press release. Underwriters can buy 2.88 million additional shares. Shares are set to trade on Nasdaq Aug. 7, 2026 under LTGO, with SEC registration effective Aug. 6.
How this was made
The 30-second read
Why it matters
The disclosed IPO terms (price, size, proceeds, underwriters, and expected listing date) are the primary actionable inputs for positioning around the listing and early trading window.
Market read
This is a fresh, company-specific capital markets event with a near-term trading date, likely increasing volatility and attention to LTGO.
What to watch
No details are provided on lockup expirations, insider ownership, underwriting allocation, or any updated clinical data, which are key drivers of post-IPO performance.
Background
Latigo is a clinical-stage biopharmaceutical company developing LTG-001, an oral Nav1.8 inhibitor for acute pain.
Ticker impact
Latigo Biotherapeutics priced its IPO at $18 and is set to start trading on Nasdaq under LTGO on Aug. 7, 2026.
Elevated first-day volatility is likely, with direction dependent on IPO demand and broader risk sentiment.
The article discloses the offer price, share count, gross proceeds, and first trading date/ticker, but provides no valuation, lockup, or demand metrics to forecast direction.
Market effects
Adds a new clinical-stage non-opioid pain drug IPO to the biotech pipeline, but without trial readouts or FDA/regulatory milestones.
Primarily US-focused via Nasdaq listing; limited direct regional spillover beyond IPO flow.
Low global relevance given the absence of international deal terms or cross-border regulatory actions.
Counterpoint
First-day moves can be dominated by IPO mechanics and market liquidity rather than LTG-001 fundamentals, so technicals and order-flow may matter more than the story.
Key entities
- companyLatigo Biotherapeutics, Inc.
Clinical-stage biopharmaceutical company pricing an IPO and preparing to list on Nasdaq as LTGO.
- product_candidateLTG-001
Oral Nav1.8 inhibitor in development for acute pain.
- venueNasdaq Global Select Market
Exchange where shares are expected to begin trading under the ticker LTGO on Aug. 7, 2026.
